Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy

By Schousboe J.   Bauer D.   Nyman J.   Kane R.   Melton L.   Ensrud K.  

Osteoporosis International, Vol. 18, Iss. 2, 2007-02 ,pp. : 201-210

Springer Publishing Company

Access to resources Recommend Favorite

Loss of treatment benefit due to low compliance with bisphosphonate therapy

By Penning-van Beest F.   Erkens J.   Olson M.   Herings R.  

Osteoporosis International, Vol. 19, Iss. 4, 2008-04 ,pp. : 511-517

Springer Publishing Company

Access to resources Recommend Favorite

Bone Mineral Density Response to Long-Term Bisphosphonate Therapy in Fibrous Dysplasia

By Parisi M.S.   Oliveri M.B.   Gómez Acotto C.   Mautalen C.A.  

Journal of Clinical Densitometry, Vol. 4, Iss. 2, 2001-03 ,pp. : 167-172

Humana Press, Inc

Access to resources Recommend Favorite

Predictors of bone loss after hip fracture

By Wehren Lois   Hawkes William   Hebel J.   Orwig Denise   Zimmerman Sheryl   Fox Kathleen   Yu-Yahiro Janet   Magaziner Jay  

Osteoporosis International, Vol. 15, Iss. 2, 2004-02 ,pp. : 125-131

Springer Publishing Company

Access to resources Recommend Favorite

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)]

By Kurland Etah   Heller Samantha   Diamond Beverly   McMahon Donald   Cosman Felicia   Bilezikian John  

Osteoporosis International, Vol. 15, Iss. 12, 2004-12 ,pp. : 992-997

Springer Publishing Company

Access to resources Recommend Favorite